Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 18/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 16/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.42 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26247973 | 1.00 | PRMT5 (0.56) | PRMT5WDR77KCNH2NAE1UBA3 | |
| SCHEMBL25387881 | 1.00 | PRMT5 (0.56) | PRMT5WDR77KCNH2NAE1UBA3 | |
| SCHEMBL26250382 | 0.89 | NAE1 (0.48) | PRMT5WDR77NAE1UBA3 | |
| SCHEMBL25387099 | 0.89 | NAE1 (0.48) | PRMT5WDR77NAE1UBA3 | |
| SCHEMBL26251193 | 0.88 | PRMT5 (0.62) | PRMT5WDR77KCNH2 | |
| SCHEMBL30493050 | 0.88 | PRMT5 (0.62) | PRMT5WDR77KCNH2 | |
| SCHEMBL25386006 | 0.88 | PRMT5 (0.62) | PRMT5WDR77KCNH2 | |
| SCHEMBL25388262 | 0.88 | PRMT5 (0.48) | PRMT5WDR77KCNH2 | |
| SCHEMBL30493033 | 0.88 | PRMT5 (0.48) | PRMT5WDR77KCNH2 | |
| SCHEMBL29501446 | 0.83 | PRMT5 (0.60) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 157/4885KCNH2 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.